Gaia Griguolo

Also affiliated with Istituto Oncologico Veneto

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial”.

Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial

European Journal of Cancer(2021)10.1016/j.ejca.2021.05.018

N/A

1.4DataRank · unranked

43 citations

Maria Vittoria Dieci, Gaia Griguolo, Federica Miglietta, Fabio Girardi, Giancarlo Bisagni +13 more

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

The Lancet Oncology(2020)10.1016/s1470-2045(20)30450-2

N/A

0.650DataRank · unranked

75 citations

Valentina Guarneri, Laia Paré, Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci +34 more